Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand

Abstract

BackgroundA prime-boost vaccination regimen with ALVAC-HIV (vCP1521) administered intramuscularly at 0, 4, 12, and 24 weeks and gp120 AIDSVAX B/E at 12 and 24 weeks demonstrated modest efficacy of 31.2% for prevention of HIV acquisition in HIV-uninfected adults participating in a community-based efficacy trial in Thailand.Methodology/Principal FindingsReactogenicity was recorded for 3 days following vaccination. Adverse events were monitored every 6 months for 3.5 years, during which pregnancy outcomes were recorded. Of the 16,402 volunteers, 69% of the participants reported an adverse event any time after the first dose. Only 32.9% experienced an AE within 30 days following any vaccination. Overall adverse event rates and attribution of relatedness did not differ between groups. The frequency of serious adverse events was similar in vaccine (14.3%) and placebo (14.9%) recipients (p = 0.33). None of the 160 deaths (85 in vaccine and 75 in placebo recipients, p = 0.43) was assessed as related to vaccine. The most common cause of death was trauma or traffic accident. Approximately 30% of female participants reported a pregnancy during the study. Abnormal pregnancy outcomes were experienced in 17.1% of vaccine and 14.6% (p = 0.13) of placebo recipients. When the conception occurred within 3 months (estimated) of a vaccination, the majority of these abnormal outcomes were spontaneous or elective abortions among 22.2% and 15.3% of vaccine and placebo pregnant recipients, respectively (p = 0.08). Local reactions occurred in 88.0% of vaccine and 61.0% of placebo recipients (p<0.001) and were more frequent after ALVAC-HIV than AIDSVAX B/E vaccination. Systemic reactions were more frequent in vaccine than placebo recipients (77.2% vs. 59.8%, p<0.001). Local and systemic reactions were mostly mild to moderate, resolving within 3 days.Conclusions/SignificanceThe ALVAC-HIV and AIDSVAX B/E vaccine regimen was found to be safe, well tolerated and suitable for potential large-scale use in Thailand.Trial Registration ClinicalTrials.gov NCT00223080

In VivoElectroporation of Minicircle DNA as a Novel Method of Vaccine Delivery To Enhance HIV-1-Specific Immune Responses

“…Although a proof of concept was demonstrated in a recent trial conducted in Thailand, significant scientific obstacles remain in improving the antigen expression and developing an efficient and safe in vivo gene delivery system (42)(43)(44). In this work, we present a novel vaccine delivery system by in vivo EP delivery of minicircle DNA carrying a codon-optimized gag gene.…”

HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials

“…The vaccine regimen was safe and generally well tolerated. 114 The modified intent-totreat analysis showed 31.2% efficacy after 42 months of follow-up. There was no effect on early postinfection HIV-1 RNA viral load or CD4 + T cell count or on clinical outcomes in longer-term follow-up.…”

Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds

“…Two groups of 5 rhesus macaques were primed with different ALVAC canarypox vectors followed by three boosts with a combination of the same ALVAC vector and a mixture of two gp120 glycoproteins from a clade B HIV-1 strain and a clade E HIV-1 strain (99,101). The group 1 monkeys were immunized with an empty ALVAC vector, whereas the group 2 monkeys were immunized with ALVAC VPC, which encodes HIV-1 Gag, Pol, and Env proteins (101). The immunization scheme in the group 2 monkeys recapitulates that used in the RV144 clinical vaccine trial in Thailand, which resulted in ϳ32% protection from HIV-1 acquisition (12).…”